More Companion Diagnostic Deals For Qiagen And Myriad
This article was originally published in The Gray Sheet
Executive Summary
Qiagen’s agreement Tokai Pharmaceuticals targets circulating tumor cells, and Myriad Genetics has extended its partnership with BioMarin Pharmaceutical focused on Myriad's myChoice HRD companion diagnostic.